Franklin Genomic Advancements ETF
Russell 3000 TR USD
NAV as of
4 Week: 28.79 - 30.91
52 Week: 28.62 - 37.61
Latest Closing Price
Premium / Discount
The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Main Fund Characteristics
|Period||Performance Returns(%)||Volatility(%)||Risk Adjusted Performance|
Annual Performance Return
|Ex Date||Payment Date||Dividend Payout per unit|
Total Number of Holdings: 58
Number of Bond Holdings: 0
Number of Equity Holdings: 55
Total Market Value: 10,347,972
Top 10 Holdings
|% Portfolio Weight||Shares Owned||Shares Changed||Market Value|
|1||Thermo Fisher Scientific Inc||6.6033||1,224||0||683,310|
|Size||% of portfolio|
Equity Style Box Breakdown
*Forward-looking based on historical data.
Number of Bond Holdings
|Average Effective Duration||0|
|Average Effective Maturity (Years)*||0|
|Average Credit Quality||0|
|Average Weighted Coupon*||0|
|Average Weighted Price*||0|
Bond Style Box Breakdown
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.